Page last updated: 2024-12-05

bromouracil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Bromouracil: 5-Bromo-2,4(1H,3H)-pyrimidinedione. Brominated derivative of uracil that acts as an antimetabolite, substituting for thymine in DNA. It is used mainly as an experimental mutagen, but its deoxyriboside (BROMODEOXYURIDINE) is used to treat neoplasms. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5-bromouracil : A pyrimidine having keto groups at the 2- and 4-positions and a bromo group at the 5-position. Used mainly as an experimental mutagen. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5802
CHEMBL ID144730
CHEBI ID20552
SCHEMBL ID29805
SCHEMBL ID8740942
MeSH IDM0002954

Synonyms (64)

Synonym
AC-3034
5-bromopyrimidine-2,4-diol
5-bromo-2,4-dihydroxypyrimidine
5-bromo-1h-pyrimidine-2,4-dione
AC-907/25014019
bromouracil
nsc19940
51-20-7
uracil, 5-bromo-
2,3h)-pyrimidinedione, 5-bromo-
nsc-19940
5-bromouracil
CHEBI:20552 ,
1,2,3,4-tetrahydro-5-bromo-2,4-pyrimidinedione
5-bromopyrimidine-2,4(1h,3h)-dione
2,4(1h,3h)-pyrimidinedione, 5-bromo-
inchi=1/c4h3brn2o2/c5-2-1-6-4(9)7-3(2)8/h1h,(h2,6,7,8,9
EU-0035288
URB ,
STK301806
5-bromouracil, 98%
uracil, 5-bromo- (van)
einecs 200-084-0
nsc 19940
5-bromo-2,4(1h,3h)-pyrimidinedione
ai3-25471
SR-01000636400-1
B-9200
B0665
CHEMBL144730
AKOS001448866
EN300-51230
BBL013052
AKOS009097562
CCG-46723
4hk400g5uo ,
hsdb 7495
5-bru
unii-4hk400g5uo
5-bu
BP-12090
FT-0602493
AB00570
EPITOPE ID:138109
5-bromouracil [mi]
AM83917
SCHEMBL29805
5-bromo-uracil
5-bromo-1,2,3,4-tetrahydropyrimidine-2,4-dione
DTXSID2058758
SCHEMBL8740942
STR01501
2,4-pyrimidinedione, 1,2,3,4-tetrahydro-5-bromo
5-bromo-2,4(1h,3h)-pyrimidinedione #
mfcd00006017
STL451516
CS-W001982
Z275128628
SY003631
5-brom-6-hydroxypyrimidinon
bromhydroxypyrimidinon
F3096-1702
Q238477
HY-W001982

Research Excerpts

Overview

5-Bromouracil is a nucleobase analogue that can replace thymine in DNA strands and acts as a strong radiosensitizer. It has potential applications in molecular biology and cancer therapy.

ExcerptReferenceRelevance
"5-Bromouracil is a nucleobase analogue that can replace thymine in DNA strands and acts as a strong radiosensitizer, with potential applications in molecular biology and cancer therapy. "( Insights into the deactivation of 5-bromouracil after ultraviolet excitation.
González, L; Mai, S; Peccati, F, 2017
)
1.45
"5-Bromouracil is an attractive photoreactive thymine analogue that can be used to investigate electron transfer in DNA, and is a useful probe for protein-DNA interaction analysis."( Electron injection from mitochondrial transcription factor A to DNA associated with thymine dimer photo repair.
Hashiya, F; Ito, S; Sugiyama, H, 2019
)
1.07

Toxicity

ExcerptReferenceRelevance
" This procedure provides the following advantages: 1) it uses common, affordable mammalian cells (HeLa cells, WI38VA13 cells, human dermal fibroblasts, or Chinese hamster ovary cells) rather than genetically modified microorganisms; 2) it can be completed within approximately 8 hr after the cells are prepared because RNA polymerase responses during TC-NER are faster than other DNA damage responses (replication, recombination, and apoptosis); and 3) it is safe because it uses non-radioactive bromouridine and antibodies to detect RNA synthesis on undamaged transcribed DNA strands."( A method for detecting genetic toxicity using the RNA synthesis response to DNA damage.
Iwai, S; Kuraoka, I; Morita, Y, 2011
)
0.37

Compound-Compound Interactions

ExcerptReferenceRelevance
"The fatal drug-drug interaction between sorivudine, an antiviral drug, and 5-fluorouracil (5-FU) has been shown to be caused by a mechanism-based inhibition."( Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil.
Ito, K; Kanamitsu, SI; Muro, K; Ogura, K; Okuda, H; Sugiyama, Y; Watabe, T, 2000
)
0.31

Dosage Studied

ExcerptRelevanceReference
" All of these rats died within 10 days, whereas rats given SRV or tegafur alone under the same dosage conditions showed no appreciable change over 20 days compared with controls."( A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Kato, A; Ogura, K; Okuda, H; Takubo, H; Watabe, T, 1998
)
0.3
" The dose-response curves (DRCs) between the observed inhibition toxicities and the doses of the pesticides or the mixtures were modeled by using the nonlinear least square fitting."( Combined photobacterium toxicity of herbicide mixtures containing one insecticide.
Liu, HL; Liu, SS; Song, XQ; Zhang, J; Zhang, YH, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mutagenAn agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pyrimidinesAny compound having a pyrimidine as part of its structure.
nucleobase analogueA molecule that can substitute for a normal nucleobase in nucleic acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1135817Retention time of the compound by liquid chromatography1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and biological activities of some uronic acids, uronates, uronamides, and urononitriles of pyrimidine nucleosides.
AID1657002Inactivation of bovine liver DHPDHase assessed as Kinact in presence of NADPH2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Acetylene Group, Friend or Foe in Medicinal Chemistry.
AID96643Cytostatic activity against proliferation of L1210/BdU cells (deoxythymidine kinase deficient L1210 cells)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis, structure, and antitumor and antiviral activities of a series of 5-halouridine cyclic 3',5'-monophosphates.
AID96642Cytostatic activity against proliferation of L1210/0 cells (murine leukemia L1210 cells)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis, structure, and antitumor and antiviral activities of a series of 5-halouridine cyclic 3',5'-monophosphates.
AID165909Cytostatic activity against proliferation of Raji/TK cells (deoxythymidine kinase deficient Raji cells)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis, structure, and antitumor and antiviral activities of a series of 5-halouridine cyclic 3',5'-monophosphates.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID165908Cytostatic activity against proliferation of Raji/0 cells (human lymphoblast Raji cells)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis, structure, and antitumor and antiviral activities of a series of 5-halouridine cyclic 3',5'-monophosphates.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (535)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990308 (57.57)18.7374
1990's70 (13.08)18.2507
2000's75 (14.02)29.6817
2010's67 (12.52)24.3611
2020's15 (2.80)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 53.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index53.24 (24.57)
Research Supply Index6.34 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index88.48 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (53.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.53%)5.53%
Reviews25 (4.46%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other533 (95.01%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]